CTIS2023-506917-23-00招募中1 期
Randomised, placebo-controlled Phase II proof of concept study of efficacy and safety of a novel rifamycin SV in situ gelling rectal solution administered by enema to patients with mild to moderate left-sided ulcerative colitis - CB-01-35/01
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 144
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Main selection criteria: Adult subjects, 18 years or older, with a diagnosis of mildly to moderately active left-sided ulcerative colitis or ulcerative proctitis will be enrolled in the study. Disease extent will be defined according to the Montreal classification of ulcerative colitis, as follows: 1.Ulcerative proctitis: involvement limited to the rectum (that is, proximal extent of inflammation is distal to the rectosigmoid junction), with 8 to 16 ± 4 cm of inflammation extent from the anal canal. 2.Left-sided ulcerative colitis (distal ulcerative colitis): involvement limited to a proportion of the colorectum distal to the splenic flexure, Informed consent: signed written informed consent before inclusion in the study, Sex and age: men/women, =18 years old inclusive, Ulcerative colitis: a =3 month old diagnosis of mildly to moderately active left-sided ulcerative colitis or ulcerative proctitis with 8 to 16 ± 4 cm of inflammation extent from the anal canal (defined by Montreal classification system of ulcerative colitis), confirmed by endoscopy and histology as follows: a. modified Mayo score =4 and =7; b. modified Mayo endoscopic subscore =2; c. Geboes histology score =2., Contraception (women only): women of childbearing potential must use at least one of the following highly effective methods of contraception. a. Hormonal combined oral, intravaginal, or transdermal, contraceptives for at least 2 months before the screening visit b. Progestogen-only hormonal oral, implantable, or injectable contraceptives for at least 2 months before the screening visit c. A non-hormonal intrauterine device or an intrauterine hormone-releasing system for at least 2 months before the screening visit d. Bilateral tubal occlusion e. A sterile sexual partner f. True abstinence, i.e., refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the subject. Women of non-childbearing potential or in post-menopausal status must have been in that status for at least one year. For all women of childbearing potential, serum pregnancy test result must be negative at screening, Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the study, Compliance with baseline diary entry: a minimum of 3 consecutive days of completed diary entries or 4 non-consecutive days within a 7-day period are necessary (not including the day of bowel preparation day and day of endoscopy), Prior and concomitant treatments: no concomitant medicines for ulcerative colitis, or mesalamine (also known as 5-ASA or mesalazine) or sulfasalazine therapy on a stable dose for at least 2 weeks prior to screening.
排除标准
- •Prior and concomitant gastrointestinal diseases: a. severe left-sided ulcerative colitis or ulcerative proctitis defined as presenting with a modified Mayo score >7 at baseline; b.ulcerative proctitis with inflammation involving less than 8 cm from the anal canal; c. extensive ulcerative colitis (defined by Montreal classification system of ulcerative colitis) extending beyond the splenic flexure (partial or total involvement of either or both the transverse colon and the ascending colon), as assessed through screening endoscopic examination and histology samples collected proximally to the splenic flexure; d. acute severe or fulminant colitis, as defined by Truelove & Witts1; e. Crohn’s disease; f. active peptic ulcer disease; g. infectious colitis; h. positive for Clostridium difficile as detected by stool test; i. current or recurrent disease that could affect the colon or the action, absorption or disposition of the study medication including diverticulitis, collagenous colitis, celiac disease, recurrent pancreatic or known gallbladder disease, toxic megacolon, fistula, perforation or abscess; j. caecal patch; k.colonic dysplasia or polypoid lesions., Prior and concomitant diseases other than gastroenteric: a. bleeding disorders; b. history of chronic liver disease (e.g. liver cirrhosis) with platelets under 50,000 and international normalised ratio >1.5; c. current or relevant previous history of serious, severe or unstable (acute or progressive) physical or psychiatric illness; d. any medical disorder that may require treatment or make the patient unlikely to fully complete the study or any condition that presents undue risk from the study medication or procedures; e. metabolic /electrolyte imbalance; f. malignancy in the last 5 years prior to screening; g. cytomegalovirus infection., Previous unsuccessful treatments: unsuccessfully treating a current relapse with steroids, Prior surgeries or medical procedures: cytapheresis therapy < 4 weeks prior to screening; previous colonic surgery (excluding appendectomy), Prior and concomitant treatments: a. systemic or rectal steroids within 2 weeks prior to baseline; b. mesalamine (also known as 5-ASA or mesalazine) or sulfasalazine therapy unless on a stable dose for at least 2 weeks before screening; c. rectal treatments other than those with steroids within 2 weeks before screening; d. immunosuppressant or immunomodulator agents including monoclonal antibodies (for instance, infliximab, adalimumab, azathioprine, 6-mercaptopurine, cyclosporine, vedolizumab, tofacitinib, filgotinib, ozanimod, etc.), within 6 weeks prior to baseline; e. ustekinumab within 16 weeks prior to baseline; f. antibiotics within 14 days before screening; g. repeatedly used non-steroidal anti-inflammatory drugs (e.g. aspirin or ibuprofen) other than mesalamine or sulfasalazine within 7 days prior to baseline. Prophylactic use of a stable dose of aspirin up to 100 mg/day for cardiac disease is permitted.
研究者
相似试验
进行中（未招募）
不适用
Clinical trial to evaluate the efficacy and safety of E-52862 for reducing oxaliplatin-induced peripheral neuropathy in patients treated for colorectal cancer.EUCTR2012-000398-21-GRaboratorios del Dr. Esteve, S.A.120
进行中（未招募）
不适用
Clinical trial to evaluate the efficacy and safety of E-52862 for reducing oxaliplatin-induced peripheral neuropathy in patients treated for colorectal cancer.OXL-induced chronic neuropathy.MedDRA version: 14.1Level: PTClassification code 10029350Term: NeurotoxicitySystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-000398-21-ESaboratorios del Dr. Esteve, S.A.120
进行中（未招募）
1 期
MedImmune Sjogren's Syndrome StudyPrimary Sjogren’s SyndromeMedDRA version: 18.1 Level: LLT Classification code 10042846 Term: Syndrome Sjogren's System Organ Class: 100000004859EUCTR2014-003896-41-GBMedImmune, LLC32
进行中（未招募）
1 期
A randomized placebo phase II study of clarithromycin or placebo combined with VCD therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myelomamultiple myelomaEUCTR2014-002187-32-DKDanish Myeloma Study Group
招募中
1 期
The Clinical Study of Yiqijiedu compound combined with anti-PD-1 antibody in the treatment of non-small cell lung cancer patients with chemotherapy resistanceITMCTR2100004241ongHua Hospital, Shanghai University of Traditional Chinese Medicine